ReviewFrontiers in veterinary science2026
Thromboembolic disease and hemostatic alterations in tumor-bearing dogs - A narrative review.
Review in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemostatic dysfunction is a prevalent and significant complication in tumor-bearing dogs, driven by complex interactions between the tumor microenvironment and the host's coagulation system. This narrative review examines primary and secondary hemostatic alterations, fibrinolytic abnormalities, and prognostic indicators associated with hemostatic variables in canine lymphoma, carcinoma, and sarcoma. In lymphoma, the true prevalence of thromboembolic disease (TED) is unknown; clinically significant hemostatic alterations are typically associated with advanced stages, characterized by persistent hypercoagulability, or elevated D-dimer concentrations, and may be associated with a poor prognosis. Carcinomas are associated with TED, and hemostatic alterations are common, typically characterized by reactive thrombocytosis, hyperfibrinogenemia, and viscoelastic evidence of hypercoagulability. Sarcomas appear to be most associated with TED. Soft tissue sarcoma and osteosarcoma exhibit different hemostatic alterations and prognostic variables compared with hemangiosarcoma, and these differences are typically related to the stage of the disease. By synthesizing current evidence, recent advances, and key knowledge gaps, this review identifies the need to define tumor-specific hemostatic diagnostic profiles in tumor-bearing dogs and subsequently develop tailored thromboprophylaxis strategies. This may ultimately improve survival by enabling targeted management of hemostatic alterations and, potentially, by mitigating metastatic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.